Premium
Wide variation of prostate‐specific antigen doubling time of untreated, clinically localized, low‐to‐intermediate grade, prostate carcinoma
Author(s) -
Choo Richard,
Klotz Laurence,
Deboer Gerrit,
Danjoux Cyril,
Morton Gerard C.
Publication year - 2004
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2004.04926.x
Subject(s) - doubling time , medicine , prostate cancer , urology , watchful waiting , prostate , prostate specific antigen , oncology , cancer , cell , chemistry , biochemistry
OBJECTIVE To assess the prostate specific antigen (PSA) doubling time of untreated, clinically localized, low‐to‐intermediate grade prostate carcinoma. PATIENTS AND METHODS A prospective single‐arm cohort study has been in progress since November 1995 to assess the feasibility of a watchful‐observation protocol with selective delayed intervention for clinically localized, low‐to‐intermediate grade prostate adenocarcinoma. The PSA doubling time was estimated from a linear regression of ln(PSA) against time, assuming a simple exponential growth model. RESULTS As of March 2003, 231 patients had at least 6 months of follow‐up (median 45) and at least three PSA measurements (median 8, range 3–21). The distribution of the doubling time was: <2 years, 26 patients; 2–5 years, 65; 5–10 years, 42; 10–20 years, 26; 20–50 years, 16; >50 years, 56. The median doubling time was 7.0 years; 42% of men had a doubling time of >10 years. CONCLUSIONS The doubling time of untreated clinically localized, low‐to‐intermediate grade prostate cancer varies widely.